Sullivan Lara → Pyxis Oncology, Inc. PYXS

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 15/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Moderate short days-to-cover (3.5 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

1 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 3.47

4,345,953 shares short · -11.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $216K

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-09-04	Civik Thomas	director, officer	Award	2,503,050	$3.89	$9.74M

Other 13D/G Filings on Pyxis Oncology, Inc.

Filed	Form	Filer	Stake	Shares
2026-10-05	SCHEDULE 13G	Coastlands Capital LP	—	—	view →
2026-10-02	SCHEDULE 13G/A	GordonMD Global Investments LP	—	—	view →
2026-07-10	SCHEDULE 13G	BIOTECHNOLOGY VALUE FUND L P	—	—	view →
2026-07-02	SCHEDULE 13G/A	GordonMD Global Investments LP	—	—	view →
2025-04-02	SCHEDULE	Sullivan Lara	11.21%	7,543,007	view →

Other Filings by Sullivan Lara

Filed	Form	Issuer	Stake	Shares
2025-04-02	SCHEDULE	Pyxis Oncology, Inc. PYXS	11.21%	7,543,007	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →